The tumor has hired security that won't let the immune system's best weapon anywhere near it
When cancer travels to bone, it does not simply invade — it negotiates, reprogramming the body's own immune sentinels into willing protectors. Researchers at Baylor College of Medicine have uncovered how metastatic tumors exploit estrogen receptor alpha signaling in bone macrophages to erect a barrier against the immune system's tumor-killing T cells. The discovery, spanning breast, lung, and kidney cancers and appearing in patients of both sexes, suggests that the bone's unusual resistance to treatment is not random but mechanistic — and therefore, potentially reversible.
- Metastatic cancer kills most patients with solid tumors, and bone metastases have long resisted treatment in ways that science could not fully explain — until now.
- A newly developed tagging technique called SAMENT allowed researchers to map the cellular neighborhood surrounding tumors, revealing that bone metastases are uniquely fortified by macrophages running estrogen receptor alpha signaling.
- Cancer cells actively engineer this defense by shipping fatty acids to nearby macrophages via extracellular vesicles, triggering a metabolic conversion that turns immune defenders into tumor bodyguards blocking T cells from ever reaching their target.
- When scientists deleted the ERα gene specifically from macrophages in mice, tumors struggled to take hold in bone, grew more slowly, and spread less — all without any damage to normal bone structure.
- The findings, published in Cell, point toward a concrete therapeutic target: disrupting ERα signaling in macrophages to strip metastatic tumors of their immune shield and restore the body's capacity to fight back.
When cancer spreads to bone, it doesn't arrive defenseless. It arrives with an escort — reprogrammed immune cells that stand between the tumor and the body's natural defenses. Researchers at Baylor College of Medicine have now mapped this arrangement in precise detail, and identified a way to dismantle it.
The key lies in a protein called estrogen receptor alpha, or ERα, and its unexpected presence in bone-dwelling immune cells called macrophages. To find it, Dr. Xiang Zhang's team developed SAMENT, a technique that selectively marks normal cells in direct contact with cancer cells, illuminating the hidden neighborhood that sustains tumor growth. What they discovered was consistent across cancer types: bone metastases were uniquely populated by ERα-active macrophages and conspicuously empty of T cells — the immune system's tumor-killing specialists.
The mechanism is both elegant and troubling. Cancer cells deliver fatty acids to nearby macrophages through extracellular vesicles, triggering a metabolic shift that activates ERα signaling. The macrophages then abandon their defensive role and form a physical and chemical barrier, preventing T cells from ever reaching the tumor. Crucially, ERα-active macrophages appeared in human bone metastasis samples from patients with breast, lung, and kidney cancers — and in male patients as well, confirming this is not a hormonal quirk but a fundamental biological strategy.
When researchers genetically removed ERα from macrophages in mice, the results were clear: tumors established themselves in bone with greater difficulty, grew more slowly, and spread less to other organs. Normal bone structure was unaffected. For the many patients whose cancers have traveled beyond their original site — the group for whom outcomes remain most dire — this points toward a specific and testable therapeutic path: blocking ERα in macrophages to restore the immune system's reach into the places tumors have learned to hide.
When cancer spreads to bone, it doesn't arrive alone. It brings an entourage of reprogrammed immune cells that stand guard against the body's natural defenses. Researchers at Baylor College of Medicine have now identified exactly how this happens—and more importantly, how to disrupt it.
The discovery centers on a protein called estrogen receptor alpha, or ERα, and its unexpected role in bone-dwelling immune cells called macrophages. For years, scientists knew that metastatic tumors in bone were particularly stubborn, resistant to treatment in ways that tumors in other organs were not. The question was why. Dr. Xiang Zhang and his team developed a new technique to find out. Called SAMENT—Sortase A–Based Microenvironment Niche Tagging—the method works by selectively marking normal cells that come into direct contact with cancer cells, revealing the cellular neighborhood that supports tumor growth.
What they found was striking. Across multiple cancer types and organs, metastatic tumors shared a common signature: lots of macrophages, very few T cells. But bone metastases were different. In bone, the macrophages had switched on ERα signaling—a protein mechanism typically associated with hormone-responsive breast cancer in women, but rarely studied in immune cells at all. The surprise deepened when researchers examined human bone metastasis samples from patients with breast, lung, and kidney cancers. ERα-active macrophages were there too, even in male patients. This was not a quirk of one cancer type or one sex. It was a fundamental mechanism.
The mechanism itself is elegant and sinister. Cancer cells deliver fatty acids to nearby macrophages through tiny particles called extracellular vesicles. These fatty acids trigger a metabolic shift inside the macrophages, turning on ERα signaling. Once activated, the macrophages stop acting like immune fighters and start acting like bodyguards. They form a physical and chemical barrier that prevents T cells—the immune system's tumor-killing specialists—from ever reaching the cancer cells. The tumor is shielded.
To test whether this was truly the mechanism driving bone metastasis, the researchers took a direct approach. They genetically removed the ERα gene specifically from macrophages in mice and watched what happened. Cancer cells struggled to establish themselves in bone. Tumors grew more slowly. Secondary metastases that typically spread from bone to other organs were reduced. Critically, removing ERα from macrophages did not damage normal bone. The skeleton remained structurally sound, its natural remodeling processes intact.
This matters because metastatic cancer—cancer that has spread beyond its original site—is the leading cause of death for most patients with solid tumors. A therapy that could disarm the immune suppression in bone metastases without harming healthy bone tissue could change outcomes for thousands of patients. The research, published in Cell, points toward a specific target: blocking ERα signaling in macrophages as a way to restore the immune system's ability to attack tumors where they hide.
Citações Notáveis
Our lab is interested in better understanding what cellular and molecular features support metastasis as these could guide the development of therapies to prevent, slow down or eliminate them.— Dr. Xiang Zhang, Baylor College of Medicine
ERα-active macrophages act as bodyguards for metastatic cancer in bone.— Fengshuo Liu, graduate student in the Cancer and Cell Biology Program
A Conversa do Hearth Outra perspectiva sobre a história
Why does bone specifically seem to be where this ERα activation happens? Is there something about bone tissue that makes it different?
That's the question the team is still working through. Bone has its own unique microenvironment—it's constantly remodeling, it has specialized cells managing that process. The cancer cells seem to exploit something about that environment, but the full picture isn't clear yet.
So the cancer cells are actively sending fatty acids to the macrophages? They're deliberately reprogramming them?
That's what the evidence suggests. The cancer cells deliver these molecules through extracellular vesicles—tiny transport particles. It's not random. It's a coordinated strategy. The macrophages don't choose to become suppressors; they're being chemically instructed to do it.
And the T cells just can't get through the barrier?
Right. The ERα-active macrophages form both physical and chemical blockades. It's like the tumor has hired security that won't let the immune system's best weapon anywhere near it.
If you remove ERα from macrophages in mice, the tumors shrink. But would that work in humans? Are there side effects we don't know about yet?
That's the next phase. The mouse studies are promising because they show the mechanism works and doesn't destroy normal bone. But human trials would need to test whether blocking ERα in macrophages causes problems elsewhere in the body. ERα is involved in other processes too.
What about the cancers that aren't in bone? Do they use a different strategy?
They seem to. The research found that other organs—lung, liver, brain—have metastatic niches with macrophages and few T cells, but without the ERα activation. So cancer has different playbooks depending on where it lands.